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Tadashi Miike1, Hisayoshi Iwakiri1, Yoshihiro Tahara1, Mitsue Sueta1, Satoru Hasuike1, Shojiro Yamamoto1, Kenji Nagata1,
Masahito Ikawa 2 and Kazuya Shimoda1
Abstract
Calreticulin (CALR) exon 9 frameshift mutations, commonly detected in essential thrombocythemia (ET) and primary
myelofibrosis patients, activate signal transducer and activator of transcription (STAT) proteins in the presence of
Myeloproliferative Leukemia Virus (MPL) and induce ET in vivo. Loss of the KDEL motif, an endoplasmic reticulum
retention signal, and generation of many positively charged amino acids (AAs) in the mutated C-terminus are thought
to be important for disease induction. To test this hypothesis, we generated mice harboring a Calr frameshift mutation
using the CRISPR/Cas9 system. Deletion of 19-base pairs in exon 9 (c.1099-1117del), designated the del19 mutation,
induced loss of the KDEL motif and generated many positively charged AAs, similar to human mutants. Calr del19
mice exhibited mild thrombocytosis, slightly increased megakaryocytes, and mild splenomegaly. In vitro experiments
revealed that the murine CALR del19 mutant had a weaker ability to combine with murine MPL than the human CALR
del52 mutant. Consequently, STAT5 activation was also very weak downstream of the murine mutant and murine MPL,
and may be the reason for the mild disease severity. In summary, loss of the KDEL motif and positively charged AAs in
the C-terminus of CALR is insufficient for MPL binding and ET development.
Introduction
Mutations in JAK2, Myeloproliferative Leukemia Virus
(MPL), or Calreticulin (CALR) are detected in more than
80% of myeloproliferative neoplasm (MPN) patients, and
these mutations are thought to play a significant role in
the pathogenesis of MPN1–7. CALR mutations are detec-
ted in approximately one-third of essential thrombo-
cythemia (ET) and primary myelofibrosis patients6,7.
Many CALR mutations have been reported, and those
most frequently observed in MPN patients are a 52-base
pair deletion (del52) or 5-base pair insertion (ins5). All of
the reported CALR mutations occur in exon 9 and cause a
frameshift that forms a new peptide in the C-terminus of
CALR6,7.
Mutant CALR augments the transcriptional activity of
signal transducer and activator of transcription (STAT) 5
in the presence of the thrombopoietin receptor, MPL,
leading to enhanced cell growth and ultimate acquisition
of cytokine-independent growth in cells expressing
MPL8–10. Mice harboring human CALR mutations
develop MPNs11–13. Activation of the JAK–STAT sig-
naling pathway by mutant CALR is the key step; however,
the underlying mechanism remains to be elucidated.
Mutant CALR binds MPL, and lectin activity of CALR is
required for this interaction8,10,14. Coupling of CALR and
MPL is required for hematopoietic cell transformation,
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but coupling alone is insufficient to induce cytokine-
independent growth14.
The C-terminus of CALR contains numerous negatively
charged amino acids (AAs) and KDEL sequences, with the
latter playing an essential role in retention of the protein
in the endoplasmic reticulum. In contrast, the C-terminal
peptide formed as a result of CALR mutations contains
many positively charged AAs, and the KDEL motif is lost.
The net positive charge of the mutant CALR C-terminus
is required for mutant CALR-mediated activation of
JAK–STAT signaling9,14. Here, we report that a frameshift
mutation in the C-terminus of murine Calr, which leads
to the formation of a new peptide sequence containing
many positively charged AAs similar to the human
counterpart del52 mutant, induces mild thrombocytosis
in vivo.
Materials and methods
Experimental details of progenitor cell assays,
fluorescence-activated cell sorting analysis, immunopre-
cipitation, western blotting, and histologic examinations
are described in the Supplemental Methods.
Cell lines and expression vector constructs
We cultured 293T cells in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum (ICN, Osaka,
Japan), penicillin/streptomycin, and L-glutamine (Invitro-
gen, Carlsbad, CA) after testing for Mycoplasma con-
tamination. Human MPL and murine Mpl cDNAs were
kindly provided by T. Nakamura15. For immunoprecipi-
tation experiments, both human MPL and murine Mpl
cDNAs were cloned into the pCMV-3Tag-4 vector (Stra-
tagene, La Jolla, CA), such that three copies of the c-Myc
epitope tag are fused to the C-terminus of the MPL pro-
tein. Human CALR wild-type (WT) cDNA (MGC clone
3898550) was purchased from DNAFORM (Yokohama,
Japan) and cloned into the pMCs-IG vector (kindly pro-
vided by Professor Toshio Kitamura, University of Tokyo,
Tokyo, Japan). CALR del52 mutant cDNA was constructed
by oligonucleotide-directed mutagenesis using a Quick-
change Site-Directed Mutagenesis kit (Stratagene) by
creating a 52-base pair deletion in the CALR WT cDNA.
Murine Calr WT cDNA (MGC clone 2655918) was pur-
chased from DNAFORM and cloned into the pMCs-IG
vector. Calr del19 mutant cDNA was constructed
according to the method described above. The percent
identity and similarity between nucleotide or AA
sequences were calculated using EMBOSS NEEDLE, an
online software program (http://emboss.bioinformatics.nl/
cgi-bin/emboss/needle).
For immunoprecipitation experiments, a FLAG tag was
fused to both the human CALR and murine Calr cDNAs.
When the FLAG tag was fused to the C-terminus of the
CALR mutant protein, the ability to activate STAT5 was
lost. When the FLAG tag was fused to the N-terminus of
the signal peptide sequence, the FLAG tag was cleaved
after synthesis of the CALR protein. Therefore, a FLAG
tag was inserted into the C-terminal portion of the signal
peptide sequence. The CALR mutant derived from this
construct retained the ability to activate STAT5 and the
FLAG tag at the N-terminus.
CRISPR/Cas9 gene editing for murine embryonic stem (ES)
cells and generation of frameshift (FS) mice
The pX330-mCalr#01 plasmid coexpressing hCas9 and
single-guide RNA was prepared by ligating oligonucleotides
(5′-CACCGAGGCTTAAGGAAGAAGAAG-3′ and 5′- AA
ACCTTCTTCTTCCTTAAGCCTC-3′) (Figure S1A) into
the BbsI site of pX330 (http://www.addgene.org/42230/) to
target murine Calr exon 9. We transfected EGR-G101
C57BL6 ES cells with the pX330-mCalr#01 and pPGK-puro
plasmids using Lipofectamine LTX & PLUS reagents (Life
Technologies, Carlsbad, CA) and selected colonies with
1.0 μg/ml puromycin for 3 days, and further cultivated the
colonies without puromycin for 5 more days16. After cloning
of ES cells, genomic DNA was extracted from each clone,
and genomic fragments containing Calr exon 9 were
amplified by polymerase chain reaction (PCR) and sequenced
with primers 5′-TTACCAAGGTGGGTCAGAGC-3′ and
5′-GCAGGGGAACAAAATCAGAA-3′. Among the four ES
clones analyzed, one clone carried compound heterozygous
mutations (del19 and del27). This mutant ES clone was
injected into eight-cell ICR embryos, and chimeric blas-
tocysts were transferred into the uterine horns of pseudo-
pregnant ICR females to generate chimeric male mice.
Germline transmission was confirmed after mating with WT
C57BL/6 female mice. In the following experiments, primer 1
(5′-CTCTTTACGCTTCTTGTCCTCTGCTCCTCATCCT
-3′), which is specific for the exon 9 mutated genomic
sequence, and primer 2 (5′-AGGATGAGGAGCAGAGGA-
CAAGAAGCGTAAAGAG-3′) were used to detect the
mutated allele. Primer 3 (5′-CTCTTTACGCTTCTTG
TCCTCTTCTTCTTCCTTAAG-3′), which is specific for
the WT exon 9 genomic sequence, and primer 2 was used to
detect the WT allele. Differential blood counts were assessed
using retroorbital eye bleeds. Mice were killed and examined
at the age of 4–6 months. The mice were divided into two
groups according to genotype. No randomization was used
for the mice to be analyzed. The investigators were blinded to
the genotype during histological examination. All procedures
were approved by the Local University of Miyazaki Ethics
Committee.
Transplantation assays
For competitive serial transplantation assays, 1 × 106
cells of each bone marrow (BM) type (B6-CD45.2) were
mixed with 1 × 106 WT BM cells (B6-CD45.1) and
transplanted into B6-CD45.1 mice. At 16 weeks after the
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first transplantation, a second transplantation was carried
out by transferring 1 × 106 BM cells from the first
recipients.
Luciferase assay
The STAT5-LUC plasmid, which contains five copies of
the STAT5 response element with a luciferase gene, was
purchased from Promega (cat. no. E465A; Fitchburg, WI).
We transfected 293T cells with WT human CALR, the
human CALRdel52 mutant, WT murine Calr, or the
murine Calr del19 mutant and either human MPL or
murine Mpl, together with the STAT5-LUC plasmid,
using calcium phosphate precipitation. Promoter activity
was measured as luciferase activity 48 h after transfection.
Luciferase activity was assayed using a Lumat LB9507
luminometer (Berthold, Wildbad, Germany). The results
of the reporter assays represent the average values for
relative luciferase activity generated in three independent
experiments.
Statistical analysis
The results are presented as the means ± SEM. To
assess the statistical significance of differences between
two groups, a two-tailed Student’s t test was used. For
comparison of hematologic results between FS and WT
mice, analysis of variance with repeated measures was
used. Statistical analysis of differences in survival was
performed using the log-rank test.
Results
Generation of mice with the Calr frameshift mutation
The AA sequence of CALR is highly conserved between
humans and mice, and 377 of 400 residues of murine
CALR are identical to the human protein (94.3% identity).
The product of exon 9 exhibits 87.9% identity and 97.0%
similarity in the AA sequence and 82.4% identity and
similarity in the nucleotide sequence of the coding region
(Fig. 1a; S1A). We set the single-guide RNA target on the
murine counterpart of the deleted nucleotides in the
human CALR del52 mutant and introduced a small
deletion in Calr exon 9 in murine ES cells using the
CRISPR/Cas9 system. Four clones with Calr mutations
were obtained, including one clone with a+ 1 frameshift
mutation: a −19/−27 mutation (clone 1), a −6/−9
mutation (clone 2), a −6/−8 mutation (clone 3), and a
−6/−6 mutation (clone 4) (Figure S1B). The 19-base pair
deletion in Calr (c.1099-1117del), designated del19,
induced a frameshift that resulted in a new C-terminal
peptide sequence including numerous positively charged
AAs, similar to the human CALR del52 mutant. Although
alignment analysis of the common AA sequence of the
human CALR mutant in exon 9 showed an identity of
59.6% between the human CALR del52 mutant and
murine CALR del19 mutant, the similarity was 72.3% (Fig.
1b; S1A). Accordingly, we chose an ES clone with the Calr
−19/−27 mutation and generated Calr del19 FS mice.
The progeny exhibited a Mendelian ratio, developed to
adulthood, and survived as long as WT mice (data not
shown).
Calr del19 FS mice demonstrated a slight increase in
platelet and megakaryocyte numbers
Peripheral blood leukocyte counts and hemoglobin
levels were comparable between WT (n= 30) and Calr
del19 FS mice (n= 36) (Fig. 2a, left; Table S1). The pla-
telet count was slightly but consistently higher in FS mice
compared with WT mice. The proportions of Mac1/Gr1
myeloid cells, B220-positive B cells, and CD3-positive
Fig. 1 Analysis of protein alignment in exon 9 of human and murine CALR. a Alignment analysis in exon 9 of human and murine WT CALR
revealed 87.9% identity and 97.0% similarity in the amino acid sequences. b Analysis of the alignment between the common amino acid sequence of
human CALR mutants and the counterpart murine CALR mutant. The amino acid sequences of the C-terminal portions of the human CALR del52
mutant and murine CALR del19 mutant are shown. The analysis revealed an identity of only 59.6% but a similarity of 72.3%. Negatively charged
amino acids are indicated in blue letters, and positively charged amino acids are indicated in red letters. Alignment analyses were performed using
EMBOSS NEEDLE, an online software program (http://emboss.bioinformatics.nl/cgi-bin/emboss/needle)
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T cells among peripheral blood leukocytes were com-
parable between the two groups (Fig. 2a, right).
The number of megakaryocytes in the BM was greater
in FS mice than WT mice (Fig. 2b). The megakaryocytes
in FS mice matured normally (Figure S2A), but there was
no difference in the diameter of megakaryocytes between
the two groups (Figure S2B). BM cellularity at 6 months
was comparable between the two groups, and no BM
fibrosis was observed upon Gomori silver staining in FS
mice over a period of 2 years of observation (Fig. 2b).
Fluorescence-activated cell sorting analysis showed a
higher proportion of CD41-positive megakaryocytes in FS
Fig. 2 Calr del19 FS mice develop mild thrombocytosis. a, left: Average complete blood cell count in FS mice every 4 months after birth (n= 36).
Compared with WT mice (n= 30), FS mice showed mild thrombocytosis from 4 months onward. No differences were found in white blood cell
(WBC) count or hemoglobin (Hb) level between WT and TG mice. *P < 0.05 and **P < 0.01 vs. WT mice. Right: Hematopoietic compartment of
peripheral blood (PB) assessed by flow cytometry. At 16 weeks of age, the proportions of myeloid cells (Mac1/Gr1) and T (CD3) and B (B220)
lymphocytes were comparable between WT (n= 23) and FS (n= 26) mice. b, left: Histologic analysis of BM. BM was stained with hematoxylin and
eosin (HE) at 6 months of age (a, b) and with Gomori silver stain at 2 years of age (c, d). FS mice exhibited increased numbers of megakaryocytes in
the BM (black arrowheads) (b). No fibrosis was found in the BM (d). Right upper: The number of megakaryocytes per 10 high-power fields (HPF) in the
BM was higher in FS mice (n= 5) than WT mice (n= 5). Right lower: The number of nucleated cells in one femur and one tibia from FS mice (n= 10)
and WT mice (n= 9) was determined at 6 months of age, and no difference in cellularity was observed. c Proportions of myeloid cells (Mac1/Gr1), B
cells (B220), T cells (CD3), megakaryocytes (CD41), and erythroid cells (CD71/Ter119 and Ter119) in the BM. The proportion of CD41-positive
megakaryocytes is higher in FS mice (n= 8) than that in WT mice (n= 6). All data are presented as the means ± SEM. *P < 0.05, **P < 0.01; NS, not
significant vs. WT mice. To assess the statistical significance between two groups, a two-tailed Student’s t test was used. For comparison of
hematologic values between FS and WT mice, analysis of variance with repeated measures was used
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mice (n= 8) than that in WT mice (n= 6), but the pro-
portions of all other cell lineages were comparable
between the two groups (Fig. 2c).
We next investigated the frequencies of hematopoietic
stem cells (HSCs) and progenitors in the BM. We found
no difference in the frequency of progenitor cells in FS
mice compared with WT mice (Fig. 3a). To assess quali-
tative differences among HSCs with Calr mutations, we
performed colony-replating assays of BM cells isolated
from WT and FS mice. We found no differences in the
number of colonies in the primary and successive platings
between WT and FS mice (Fig. 3b). The Calr del19
mutation did not increase the sequential colony-replating
capacity.
Next, we examined whether the Calr del19 mutation
conferred any growth advantage by transplanting WT or
Calr del19 mutant BM cells (B6-CD45.2) together with
competitor WT BM cells (B6-CD45.1) in a 1:1 ratio into
lethally irradiated recipients (B6-CD45.1) and then con-
tinuing with serial transplantations. The transplanted
Calr del19 mutant cells exhibited higher peripheral blood
chimerism in the first recipients than did the transplanted
WT cells, but the clonal advantage conferred by the
mutation in the primary recipients was not observed in
the secondary transplant recipients (Fig. 3c). In this
competitive transplantation assay, the platelet count was
also examined in recipient mice. In primary recipients,
average platelet counts were slightly higher in mice
transplanted with FS cells (n= 10) than in mice trans-
planted with WT cells (n= 10), but the difference was not
significant (p= 0.14) (Figure S3). This might be caused by
the small extent of thrombocytosis in recipient mice, and
the detection power was insufficient with the number of
mice used in this experiment.
Extramedullary hematopoiesis in the spleen of Calr del19
FS mice
The spleen is a hematopoietic organ in mice17, and the
spleen harbors HSCs that are functionally equivalent to
those in the BM, albeit at a lower frequency. An exam-
ination of the spleen in Calr del19 FS mice revealed mild
splenomegaly, with elevated spleen weight and total cell
number compared with WT mice (Fig. 4a). On the other
hand, the liver weight of FS mice was equivalent to that of
WT mice (Figure S4).
On splenic histology, the margin of white pulp was
obscured in some FS mice compared with WT mice
(Figure S5a, d). In such FS mice, high-magnification
Fig. 3 Analysis of HSCs/progenitor cells. a Proportions of HSCs and progenitors. No differences were found in the frequencies of any progenitors
between WT mice (n= 8) and FS mice (n= 8). b Enumeration of colonies and the serial replating capacity of 5 × 104 BM cells from WT (n= 8) and FS
(n= 8) mice. FS BM cells did not exhibit enhanced sequential colony-replating capacity. c Serial transplantation assays. WT or FS BM cells (B6-CD45.2)
together with competitor WT BM cells (B6-CD45.1) were transplanted at a 1:1 ratio into lethally irradiated recipients (B6-CD45.1) (n= 14 in each
group), and then 1 × 106 recipient BM cells were transplanted into a second set of lethally irradiated recipients (B6-CD45.1) (n= 14 in each group).
Chimerism of donor-derived CD45.2+ cells in peripheral blood at 16 weeks after the first and second transplantations is shown. All data are
presented as the means ± SEM. *P < 0.05; NS, not significant vs. WT cells. A two-tailed Student’s t test was used
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observation clearly showed infiltration of large myeloid
cells including megakaryocytes to the red pulp (Figure
S5b, c, e, f), but there was no difference in the number of
megakaryocyte progenitor cells in the spleens between
FS mice and WT mice (9.1 ± 4.1 × 103, 7.0 ± 2.5 × 103,
respectively, p= 0.31). Colony-forming unit (CFU)-
granulocyte, erythrocyte, macrophage, megakaryocyte,
CFU-granulocyte–macrophage, and CFU-erythroid in
the whole spleen were greater in FS mice than WT mice
(Fig. 4b). With regard to HSCs and progenitor cells, the
numbers of Lin−cKit+ cells, granulocyte/macrophage
progenitor cells, and megakaryocyte/erythrocyte pro-
genitor cells in the whole spleen were greater in FS mice
than WT mice (Fig. 4c). Although the numbers of CFUs
and progenitor cells in the spleen were higher in FS
mice, the proportions of these cells were larger (though
not significantly different) from those of WT mice
(Figure S6).
Murine CALR del19 mutant augmented STAT5
transcription activity in the presence of human MPL, but
the effect was minimal in the presence of murine MPL
Calr del19 FS mice exhibited a slight increase in the
number of platelets and megakaryocytes in the peripheral
blood and BM, respectively, and exhibited extramedullary
hematopoiesis in the spleen, demonstrating that Calr
del19 FS mice developed mild ET. These results are
consistent with previous observations of our group and
others in which mice expressing human CALR mutations
develop ET11,12; however, disease severity differs drama-
tically between them. Mice expressing human CALR
mutations develop severe thrombocytosis and an
approximately twofold increase in the number of BM
megakaryocytes compared with WT mice, whereas mice
expressing murine Calr mutations develop very mild
thrombocytosis, with an ~1.3-fold increase in the number
of BM megakaryocytes compared with WT mice.
Fig. 4 Extramedullary hematopoiesis in the spleen of Calr del19 FS mice. a Spleen weight of 4- to 6-month-old mice. FS mice (n= 8) exhibited
mild splenomegaly compared with WT mice (n= 8). The number of nucleated cells in the spleen of WT mice (n= 8) and FS mice (n= 8) was
determined. FS mice exhibited enhanced cellularity compared with WT mice. b The number of hematopoietic colonies in the spleen was calculated
from the “number of colonies per unit cell number” and “total cell number”. The CFU-GEMM, CFU-GM, and CFU-E in the spleen were greater in FS
mice than WT mice. c The numbers of HSCs and progenitor cells in the spleen were calculated from “the proportion of each cell fraction” and “total
cell number”. Numbers of Lin−cKit+ cells, GMP cells, and MEP cells were significantly higher in the spleen of FS mice. All data are presented as the
means ± SEM. *P < 0.05, **P < 0.01; NS, not significant vs. WT mice. A two-tailed Student’s t test was used
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STAT5 activity is indispensable for normal mega-
karyocyte development, as demonstrated by impaired
platelet production in STAT5-deficient mice18. We and
others previously reported that the human CALR del52
mutant augments STAT5 transcription activity in the
presence of MPL in 293T cells. We therefore transiently
transfected 293 T cells with human WT CALR, human
CALR del52 mutant, murine WT Calr, or murine Calr
del19 mutant, together with either humanMPL or murine
Mpl, and STAT5-LUC (Fig. 5a). The murine Calr del19
mutant augmented STAT5 activity in the presence of
human MPL, similar to the case with the human CALR
del52 mutant; however, augmentation of STAT5 activity
in the presence of murine MPL was comparatively weak.
Binding to mutant CALR is necessary for activation of
MPL. Therefore, we compared binding of the human
CALR del52 mutant (FLAG-tagged) and murine CALR
del19 mutant (FLAG-tagged) to human MPL (Myc-tag-
ged) using immunoprecipitation. Binding between each
mutant and murine MPL (Myc-tagged) was simulta-
neously investigated. Human MPL bound very strongly to
the human CALR mutant and moderately to the murine
CALR mutant. Interestingly, murine MPL bound very
strongly to the human CALR mutant, but only very
weakly to the murine CALR mutant (Fig. 5b).
Discussion
Many types of human CALR exon 9 mutants have been
reported in ET and PMF patients. In all human CALR
exon 9 mutants, a new AA sequence appears in the C-
terminal portion of the protein as a result of the+ 1 fra-
meshift. In the newly synthesized C-terminus, the KDEL
motif, which acts as an endoplasmic reticulum localiza-
tion signal, is lost, and charge inversion occurs, in which
the WT sequence containing numerous negatively
charged aspartic acid and glutamic acid residues are
replaced with positively charged arginine and lysine resi-
dues6,7. The C-terminus resulting from the murine Calr
del19 mutation that we created exhibits characteristics
very similar to those of the C-terminus of the human
CALR mutant: loss of the KDEL sequence and reversal of
net charge from negative to positive. Furthermore, the AA
sequence similarity in the mutated portion of the protein
derived from exon 9 is 72.3%. However, Calr del19 FS
mice showed only minimal thrombocytosis and slight
extramedullary hematopoiesis in the spleen and did not
reproduce the full phenotype of ET. We also generated
mice with a c.1155delA (p.E386fs*44) mutation (which is
also a+ 1 frameshift mutation) at a site closer to the C-
terminus than the Calr del19 mutation. However, no
significant MPN development was observed in the FS
mice (data not shown). The absence of the full MPN
phenotype in mice with two different+ 1 frameshift
mutations suggests that the number of bases deleted and
the starting point of the frameshift are not significant.
Indeed, Balligand et al. reported the generation of Calr
del61 FS mice using the same methods we used, and these
mice exhibited mild thrombocythemia19.
The mechanism of how human mutant CALR induces
MPN has not been fully clarified. We and others pre-
viously showed that human CALR mutants augment
STAT5 transcriptional activity in the presence of MPL,
but neither in the presence of erythropoietin receptor nor
colony-stimulating factor 3 receptor8–10,12,13. Araki et al.
reported that mutant CALR forms homomultimers and
binds to MPL20. These reports strongly suggest that the
binding of mutant CALR to MPL is required for activation
of the MPL downstream JAK–STAT signaling cascade
and development of MPN. We then examined the binding
between the murine frameshift mutant and MPL. In vitro
experiments using 293T cells revealed that the murine
CALR del19 mutant binds weakly to human and murine
MPL compared with the human CALR del52 mutant. In
particular, binding to murine MPL was weaker than
binding to human MPL, and as a result, STAT5 activation
downstream of MPL (which is essential for MPN induc-
tion) was also very weak. This could be the cause of the
Fig. 5 Weak activation of MPL-STAT5 signaling by the murine
CALR del19 mutant. a STAT5 transcription activity measured using a
luciferase assay. 293T cells were transiently transfected with STAT5-
LUC and the CALR WT, CALR del52 mutant, Calr WT, or Calr del19
mutant in the presence of the human thrombopoietin receptor (MPL)
or murine Mpl. The y-axis indicates the fold induction of luciferase
activity compared with WT CALR. *P < 0.05, **P < 0.01; NS, not
significant vs. WT CALR. The average values for relative luciferase
activity generated in three independent experiment are shown. Data
are presented as means ± SEM. A two-tailed Student’s t test was used.
b Binding of human or murine CALR mutant (FLAG-tagged) to human
or murine MPL (Myc-tagged) examined by immunoprecipitation and
western blot analysis. Binding between the murine CALR del19
mutant and murine MPL was weakest in comparison with the other
three combinations
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absence of a full ET phenotype exhibited by Calr del19 FS
mice. The lectin-binding sites (D135 and D317) of human
CALR, which are necessary for binding between human
mutant CALR and human MPL14, are conserved in
murine CALR. Li et al. created knock-in (KI) mice har-
boring hybrid Calr, in which only exon 9 of murine Calr
was replaced with human CALR exon 9 with the del52
mutation11. They could not confirm binding between the
murine MPL and hybrid CALR in vivo, but did report a
prominent ET phenotype. These observations suggest that
the weak binding between the murine CALR del19
mutant and human and murine MPL is not due to the 6%
difference in the AA sequence encoded by exons 1
through 8. Differences in the AA sequence encoded by
exon 9 between the human and murine mutants may lead
to differences in binding affinity to MPL. Elf et al.
reported that a net positive charge in the C-terminus of
the CALR mutant is required for transformation of
human MPL and Ba/F3 cells, rather than a specific
sequence within the mutant CALR C-terminus9. Contrary
to their hypothesis, the reversal of net charge from
negative to positive in the murine CALR del19 mutant
was not sufficient for binding to murine MPL, although
the murine del19 mutant also contained as many posi-
tively charged AAs as human mutant CALR. Our results
indicate that the C-terminal sequence of the human
mutant in which positive charges are intermittently
aligned may contain AA sequence motifs important for
binding to MPL.
Human CALR del52 mutant transgenic (TG) mice that
we previously generated exhibit a higher proportion of
HSCs in the BM than WT mice12. Competitive repopu-
lation experiments using 4000 sorted Lin−Sca-1+cKit+
cells showed that the chimerism exhibited by mutant cells
in recipient mice was significantly lower than that
exhibited by WT cells (manuscript in preparation). In KI
mice generated by Li et al., the chimerism of mutant cells
was equivalent to that of WT cells in competitive repo-
pulation experiments using BM cells, although the pro-
portion of HSCs in the BM of KI mice was greater than
that observed in WT mice. These results indicate that the
competitive repopulation capacity of HSCs with the
human CALR del52 mutation is inferior to that of WT
HSCs. As reported for the JAK2 V617F mutation21, this
defect may be due to the exhaustion of HSCs by over-
activation of MPL-STAT5 signaling. In Calr del19 FS
mice, the proportion of HSCs among BM cells was
comparable with that in WT mice, and in competitive
repopulation experiments using BM cells, the chimerism
of Calr del19 cells was greater than that of WT cells in the
primary transplant recipients. Activation of MPL-STAT5
signaling by the murine CALR del19 mutant was very
weak compared with the human CALR del52 mutant, and
this difference in the strength of signal activation may
result in differences in the number and quality of HSCs.
In contrast, no difference was observed between murine
Calr del19 cells and WT cells in the secondary transplant
recipients, as was reported for TG mice and human CALR
exon 9 KI mice11,12.
In summary, mice with a+ 1 frameshift mutation in
Calr did not show the full phenotype of MPN. This was
due to decreased binding between mutant CALR and
MPL and the dramatic reduction in activation of MPL
downstream signaling cascades. AA sequence motifs that
are important for binding to MPL may be present in the
C-terminal sequence of the human CALR frameshift
mutant.
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